Multi-center Performance Evaluations of Tacrolimus and Cyclosporine Electrochemiluminescence Immunoassays in the Asia-Pacific Region.
- Author:
Xuzhen QIN
1
;
Jianzhong RUI
;
Yong XIA
;
Hong MU
;
Sang Hoon SONG
;
Raja Elina RAJA AZIDDIN
;
Gabrielle MILES
;
Yuli SUN
;
Sail CHUN
Author Information
- Publication Type:Multicenter Study ; Original Article
- Keywords: Cyclosporine; Tacrolimus; Immunosuppressant drugs; Immunoassay; Therapeutic drug monitoring; Asia-Pacific
- MeSH: Absorption; China; Cyclosporine*; Drug Monitoring; Heart; Humans; Immunoassay*; Korea; Liver; Malaysia; Methods; Tacrolimus*; Transplants
- From:Annals of Laboratory Medicine 2018;38(2):85-94
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: The immunosuppressant drugs (ISDs), tacrolimus and cyclosporine, are vital for solid organ transplant patients to prevent rejection. However, toxicity is a concern, and absorption is highly variable across patients; therefore, ISD levels need to be precisely monitored. In the Asia-Pacific (APAC) region, tacrolimus and cyclosporine concentrations are typically measured using immunoassays. The objective of this study was to assess the analytical performance of Roche Elecsystacrolimus and cyclosporinee electrochemiluminescence immunoassays (ECLIAs). METHODS: This evaluation was performed in seven centers across China, South Korea, and Malaysia. Imprecision (repeatability and reproducibility), assay accuracy, and lot-to-lot reagent variability were tested. The Elecsys ECLIAs were compared with commercially available immunoassays (Architect, Dimension, and Viva-E systems) using whole blood samples from patients with various transplant types (kidney, liver, heart, and bone marrow). RESULTS: Coefficients of variation for repeatability and reproducibility were ≤5.4% and ≤12.4%, respectively, for the tacrolimus ECLIA, and ≤5.1% and ≤7.3%, respectively, for the cyclosporine ECLIA. Method comparisons of the tacrolimus ECLIA with Architect, Dimension, and Viva-E systems yielded slope values of 1.01, 1.14, and 0.897, respectively. The cyclosporine ECLIA showed even closer agreements with the Architect, Dimension, and Viva-E systems (slope values of 1.04, 1.04, and 1.09, respectively). No major differences were observed among the different transplant types. CONCLUSIONS: The tacrolimus and cyclosporine ECLIAs demonstrated excellent precision and close agreement with other immunoassays tested. These results show that both assays are suitable for ISD monitoring in an APAC population across a range of different transplant types.
